CyndRx, LLC Receives Full FDA Approval of Investigational Device Exemption (IDE) to Initiate a U.S. Pivotal Trial for the AbsorbaSeal™ 5.6.7F Vascular Closure DeviceRead More
CyndRx, LLC Finalizes CE Mark Trial with Strong Clinical Outcomes using AbsorbaSeal™ Vascular Closure DeviceRead More
CyndRx, LLC Announces Completion of Enrollment in the AbsorbaSeal™ Vascular Closure Device CE Mark TrialRead More
CyndRx, LLC Enrolls First Patients in the AbsorbaSeal™ Vascular Closure Device CE Mark TrialRead More
CyndRx, LLC announces European trial to support CE Mark of the AbsorbaSeal™ Vascular Closure DeviceRead More
